3-(benzoylamino)piperidine-1-carboxylic acid tert-butyl ester | 478645-89-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(benzoylamino)piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 3-(benzoylamino)piperidine-1-carboxylate；tert-butyl 3-benzamidopiperidine-1-carboxylate
• CAS: 478645-89-5
• 化学式: C₁₇H₂₄N₂O₃
• 分子量: 304.389
• InChiKey: VAULERMLVIMBCU-UHFFFAOYSA-N

物化性质

• 沸点：
  478.8±38.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(benzoylamino)piperidine-1-carboxylic acid tert-butyl ester 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 48.0h， 以22%的产率得到N-(3-piperidinyl)benzamide
  参考文献：
  名称：

  Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers

  摘要：

  A series of 2-oxopiperazine, 4-aminomethyl-, 3-amino- and 3-aminomethylpiperidine analogues of DM235 (sunifiram) and MN19 (sapunifiram), two previously reported potent cognition-enhancers, have been synthesized and tested in the mouse passive-avoidance test. The compounds display minimal effective doses in the range 0.3-10 mg/kg. Although the new substances do not show improved activity when compared to the parent compounds, some useful information has been obtained to understand structure-activity relationships. In addition, the 3-aminopiperidine moiety appears to be a promising scaffold to synthesize new drugs endowed with cognition-enhancing activity. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.050
• 作为产物：
  描述：

  tert-butyl benzoyl(benzyl)carbamate 、 1-叔丁氧羰基-3-氨基哌啶 在 air 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以67%的产率得到3-(benzoylamino)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  以N-Boc酰胺为底物合成酰胺类化合物的方法

  摘要：

  本发明涉及一种以N‑Boc酰胺为底物合成酰胺类化合物的方法。该方法是在有机溶剂中，N‑Boc酰胺与各种胺类化合物发生分子间亲核取代反应，可以高效地得到各种酰胺类化合物。该方法具有反应条件温和、操作简便、产率高、官能团兼容性良好的优点。

  公开号：

  CN110627745A

文献信息

• [EN] PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA<br/>[FR] DERIVES PYRROLIDINE-2-UN COMME INHIBITEURS DE FACTEUR XA
  申请人：GLAXO GROUP LTD

  公开号：WO2002100886A1

  公开（公告）日：2002-12-19

  The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明涉及式(Ic)化合物、其制备过程、含有它们的药物组合物以及它们在医学上的应用，特别是在改善适用于因子Xa抑制剂的临床状况方面的应用。
• Chemical compounds
  申请人：Chan Chuen

  公开号：US20060160886A1

  公开（公告）日：2006-07-20

  The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明涉及式(Ic)化合物，其制备方法，含有它们的药物组合物以及它们在医学上的应用，特别是在改善适应于Xa因子抑制剂的临床状况方面的应用。
• Pyrrolidin-2-one derivatives as inhibitors of factor xa
  申请人：——

  公开号：US20040152697A1

  公开（公告）日：2004-08-05

  The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated. 1

  本发明涉及公式（Ic）化合物，它们的制备过程，含有它们的药物组合物，以及它们在医学上的应用，特别是在改善适合使用因子Xa抑制剂的临床症状方面的应用。
• Pyrrolidin-2-one derivatives as inhibitors of factor Xa
  申请人：SmithKline Beecham Corporation

  公开号：US07084139B2

  公开（公告）日：2006-08-01

  The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  该发明涉及式(Ic)的化合物、制备它们的方法、含有它们的药物组合物以及它们在医学上的使用，特别是在改善适应于Xa因子抑制剂的临床状况方面的使用。
• Chemicals compounds
  申请人：GLAXO GROUP LIMITED

  公开号：EP1839659A2

  公开（公告）日：2007-10-03

  The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明涉及式 (Ic) 的化合物 的制备工艺、含有它们的药物组合物以及它们在医学中的用途，特别是在改善Xa因子抑制剂适用的临床症状中的用途。